Moscow: The Clinical Center of I. M. Sechenov First Moscow State Medical University (Sechenov University) has initiated eardrum repair procedures utilizing tissue equivalents derived from patients' own cells, as reported by TV BRICS. This development marks a significant milestone in medical science, being the first reported clinical application of a cell-based medicinal product (CBMP) for eardrum regeneration globally. According to Emirates News Agency, this innovative procedure represents a full cycle achievement from fundamental research to clinical application within Sechenov University. The rector of the university, Petr Glybochko, highlighted the institution's unique position in Russia as it transitions from research to certified production and clinical implementation of cell products. The research, supported by state programmes for science and education, employs a technique involving the creation of cell spheroids from a patient's adipose tissue. These spheroids are then implanted alongside a resorbab le membrane, which eventually dissolves and is replaced by the patient's tissue, mimicking the natural structure and function of an eardrum. Clinical findings suggest that this procedure takes approximately 40 minutes, significantly shorter than traditional tympanoplasty. The initial patients have shown positive recovery outcomes post-surgery. Experts highlight that tympanic membrane perforation affects a significant number of individuals, typically resulting from infections, trauma, or sudden pressure changes. Conventional surgical approaches are intricate and often lead to graft failure in 10-20 percent of cases. This new development offers a promising alternative with the potential for more stable outcomes. Researchers assert that the comprehensive approach, from cell isolation to clinical application, facilitates the advancement from experimental research to practical medicine. They also suggest that the platform technology used could be extended to the regeneration of other organs and tissues, thereby broadening the scope of cell-based therapies in clinical settings.